Evidence map›Paper›PMID 40677320›Full record

ArticleKidney international reports2025

Holistic Impact of CKD: A Clinical, Economic, and Environmental Analysis by IMPACT CKD.

Naveen Rao, Francisco Brotons-Munto, Ana F Moura, Janwillem W H Kocks, Ming-Hui Zhao, Steven Chadban, Hannah Guiang, Stacey Priest, Stephen Brown

Abstract read
In one paragraph

Article in Kidney international reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Article
  4. [Prevention and screening in nephrology].Innere Medizin (Heidelberg, Germany) · 2026
    Article
  5. Article
  6. Lifestyle and Environment Aspects Challenging Kidney Health.Kidney & blood pressure research · 2026
    Review
  7. Review
  8. Article
  9. Cardio-kidney-metabolic (CKM) framework: A nephrologist's perspective.Archives of endocrinology and metabolism · 2025
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Naveen RaoBioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
Francisco Brotons-MuntoTrinitat Health Center, Valencia, Spain.
Ana F MouraEscola Bahiana de Medicina e Saúde Pública, Salvador, Brazil.
Janwillem W H KocksGeneral Practitioners Research Institute, Groningen, The Netherlands.
Ming-Hui ZhaoPeking University First Hospital, Beijing, China.
Steven ChadbanRoyal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
Hannah GuiangEVERSANA, Burlington, Ontario, Canada.
Stacey PriestEVERSANA, Burlington, Ontario, Canada.
Stephen BrownEVERSANA, Burlington, Ontario, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Chronic kidney disease (CKD) is a growing global health problem driven by aging and the rise of comorbidities, including diabetes and hypertension. Although clinical and economic burdens have been reported, there is a lack of information on the multidimensional impact of CKD across countries with varying demographics and health system archetypes. Methods: The validated IMPACT CKD model was used to project the clinical, health care resource use (HCRU), economic, patient, societal, and environmental burden of CKD in 8 countries (Australia, Brazil, China, Germany, Netherlands, Spain, United Kingdom, and United States) over 10 years (baseline: 2022; simulated years: 2023-2032). Results: By 2032, 11.7% to 16.5% of the countries' populations were projected to have CKD, with prevalence rising in 7 countries over 10 years, and a shift toward later stages. These increases were accompanied by projected increases of 3.6% to 170.8% and 41.9% to 80.1% in the number of patients living on dialysis and with a functioning kidney transplant, respectively. Driven by this growing clinical burden, increases of over 19% in CKD costs and 20% in kidney replacement therapy (KRT) costs were projected across all countries. Impaired work productivity led to significant projected losses in gross domestic product, full-time equivalents, and tax revenue. Freshwater consumption, fossil fuel depletion, and carbon production in patients on KRT were projected to increase by over 11% in all the countries. Conclusion: This study demonstrates the multifaceted burden of CKD globally and supports the adoption of policies such as CKD screening programs and public health awareness to promote early diagnosis and treatment to mitigate the growing disease burden.

Indexed as

chronic kidney diseasekidney replacement therapymicrosimulation epidemiology modelmultidimensional burdenpolicy

Identifiers

PMID40677320
PMCPMC12266219

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.